EGFR
Los inhibidores del receptor del factor de crecimiento epidérmico (EGFR) son compuestos que bloquean la señalización del EGFR, un receptor que a menudo está sobreexpresado en varios tipos de cáncer y que juega un papel crucial en la angiogénesis. Los inhibidores del EGFR se utilizan para prevenir el crecimiento tumoral y las metástasis al interrumpir las vías que promueven la formación de vasos sanguíneos en los tumores. Estos inhibidores son ampliamente utilizados en la investigación y terapia contra el cáncer. En CymitQuimica, ofrecemos una amplia selección de inhibidores de EGFR de alta calidad para apoyar su investigación en oncología y angiogénesis.
Se han encontrado 572 productos de "EGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tarlox-TKI
CAS:<p>Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.</p>Fórmula:C19H18BrClN6OPureza:97.03%Forma y color:SolidPeso molecular:461.74EGFR-IN-69
CAS:<p>EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.</p>Fórmula:C31H37Cl2N7O3SForma y color:SolidPeso molecular:658.64EGFR-IN-67
CAS:<p>EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].</p>Fórmula:C18H17N3SForma y color:SolidPeso molecular:307.41EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Fórmula:C17H14N4O4S3Forma y color:SolidPeso molecular:434.51EGFR-IN-21
CAS:<p>EGFR-IN-21, a potent EGFR inhibitor, exhibits an IC50 of 0.38 nM, demonstrating significant antitumor activity.</p>Fórmula:C36H44BrN10O2PForma y color:SolidPeso molecular:759.68NSC81111
CAS:<p>NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].</p>Fórmula:C19H16O4Forma y color:SolidPeso molecular:308.33EGFR-IN-73
CAS:<p>EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, exhibiting an IC50 value of 119 nM [1].</p>Fórmula:C19H17ClFN3O4Pureza:98%Forma y color:SolidPeso molecular:405.81Antiproliferative agent-34
CAS:<p>Antiproliferative Agent-34 (Compound A14), a multitarget kinase inhibitor, demonstrates IC50 values of 177 nM for EGFR L858R/T790M and 1567 nM for EGFR WT.</p>Fórmula:C27H27N7O5Pureza:98%Forma y color:SolidPeso molecular:529.55EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Fórmula:C26H31FN8O2SPureza:98%Forma y color:SolidPeso molecular:538.64AG-183
CAS:<p>(Z)-Tyrphostin A51, a Z-isomer of Lanoconazole A51, is a strong PTK inhibitor blocking [3 H]taurine release and tyrosyl phosphorylation.</p>Fórmula:C13H8N4O3Forma y color:Brown SolidPeso molecular:268.23EGFR-IN-16
CAS:<p>EGFR-IN-16 (AG473) is an inhibitor of EGFR in human A431 cells.</p>Fórmula:C16H11NO3Pureza:98%Forma y color:SolidPeso molecular:265.26(E/Z)-AG490
CAS:<p>(E/Z)-AG490 is a racemic mix of (E)- and (Z)-isomers; it inhibits tyrosine kinase, EGFR, Stat-3, and JAK2/3.</p>Fórmula:C17H14N2O3Forma y color:SolidPeso molecular:294.3EGFR-IN-75
<p>EGFR-IN-75 inhibits EGFR WT/T790M; IC50s: 0.28/5.02 μM. It has anticancer and antioxidant effects.</p>Fórmula:C10H6N6S2Forma y color:SolidPeso molecular:274.32CGP52411
CAS:<p>CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM).</p>Fórmula:C20H15N3O2Pureza:99.78%Forma y color:SolidPeso molecular:329.35EGFR-IN-50
CAS:<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Fórmula:C24H26BrN3O4S2Forma y color:SolidPeso molecular:564.51EGFR-IN-53
CAS:<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Fórmula:C14H13N3O2SForma y color:SolidPeso molecular:287.34EGFR-IN-28
CAS:<p>EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .</p>Fórmula:C31H39BrN10O3SForma y color:SolidPeso molecular:711.68NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C22H20O4Forma y color:SolidPeso molecular:348.39BAY 2476568
CAS:<p>BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).</p>Fórmula:C24H27FN4O4Forma y color:SolidPeso molecular:454.49LDC0496
CAS:<p>LDC0496: Potent EGFR/Her2 exon 20 inhibitor; selective for wild-type EGFR, kinase-specific.</p>Fórmula:C32H35N5O3Forma y color:SolidPeso molecular:537.65Lavendustin C6
CAS:<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Fórmula:C20H25NO5Forma y color:SolidPeso molecular:359.42PDZ1i
CAS:<p>PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.</p>Fórmula:C28H26N8O4Forma y color:SolidPeso molecular:538.56Nazartinib mesylate
CAS:<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Fórmula:C27H35ClN6O5SPureza:98%Forma y color:SolidPeso molecular:591.12Tyrphostin AG 112
CAS:<p>Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.</p>Fórmula:C13H8N4OPureza:97.01%Forma y color:SolidPeso molecular:236.23DBPR112
CAS:<p>DBPR112: oral furanopyrimidine EGFR inhibitor; IC50: 15 nM (EGFRWT), 48 nM (L858R/T790M); blocks ATP site, strong antitumor effects.</p>Fórmula:C32H31N5O3Pureza:99.25%Forma y color:SolidPeso molecular:533.62Epertinib
CAS:<p>Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM).</p>Fórmula:C30H27ClFN5O3Pureza:98%Forma y color:SolidPeso molecular:560.02MS 39
CAS:<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Fórmula:C55H71ClFN9O7SForma y color:SolidPeso molecular:1056.72RTC-5
CAS:<p>RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties.</p>Fórmula:C24H22ClF3N2O3SPureza:98.14%Forma y color:SolidPeso molecular:510.96SDZ281-977
CAS:<p>SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.</p>Fórmula:C18H20O5Pureza:99.64%Forma y color:SolidPeso molecular:316.35EGFR-IN-2
CAS:<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Fórmula:C26H33N9O3SPureza:98.52% - 99.79%Forma y color:SolidPeso molecular:551.66Gefitinib N-oxide
CAS:<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Fórmula:C22H24ClFN4O4Pureza:98%Forma y color:SolidPeso molecular:462.9Nimotuzumab
CAS:<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Pureza:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Forma y color:LiquidEGFR-IN-5
CAS:<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Fórmula:C31H38FN9OPureza:98.17%Forma y color:SolidPeso molecular:571.69BKI-1369
CAS:<p>BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).</p>Fórmula:C23H27N7OForma y color:SolidPeso molecular:417.51EGFR-IN-68
CAS:<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Fórmula:C24H22N2OForma y color:SolidPeso molecular:354.44JBJ-04-125-02
CAS:<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Fórmula:C29H26FN5O3SPureza:98%Forma y color:SolidPeso molecular:543.61EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Fórmula:C27H27F3N6O2SForma y color:SolidPeso molecular:556.6Mutated EGFR-IN-2
CAS:<p>Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR.</p>Fórmula:C29H35FN8O3Pureza:98%Forma y color:SolidPeso molecular:562.64GW 583340 dihydrochloride
CAS:<p>GW 583340 dihydrochloride is a potent and orally available dual EGFR/ErbB2 inhibitor and inhibits 80% of tumor growth in a mouse xenograft mode.</p>Fórmula:C28H27Cl3FN5O3S2Pureza:98.80%Forma y color:SolidPeso molecular:671.03EGFR-IN-64
CAS:<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Fórmula:C20H21N3O3Forma y color:SolidPeso molecular:351.4JNJ28871063 hydrochloride
CAS:<p>ErbB receptor family inhibitor</p>Fórmula:C24H28Cl2N6O3Pureza:98%Forma y color:SolidPeso molecular:519.42Mutated EGFR-IN-3
CAS:<p>Mutated EGFR-IN-3: ATP-competitive, selective dibenzodiazepinone inhibitor for EGFR mutations, IC50 12-13 nM.</p>Fórmula:C31H29FN4O2Pureza:98%Forma y color:SolidPeso molecular:508.59EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Fórmula:C24H25ClN6O3Forma y color:SolidPeso molecular:480.95Selatinib
CAS:<p>Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.</p>Fórmula:C29H26ClFN4O3SPureza:98.00%Forma y color:SolidPeso molecular:565.06EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Fórmula:C21H20N2O3Forma y color:SolidPeso molecular:348.4EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Fórmula:C25H25Cl2N7O2Forma y color:SolidPeso molecular:526.42EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Fórmula:C22H15N5O2SForma y color:SolidPeso molecular:413.45EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Fórmula:C32H36FN7O2Forma y color:SolidPeso molecular:569.67EGFR/HER2-IN-3
CAS:<p>EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.</p>Fórmula:C26H23N5O3Forma y color:SolidPeso molecular:453.49
